Loss of BAP1 expression is very rare in pancreatic ductal adenocarcinoma

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Tayao, Michael ^a,b   Andrici, Juliana ^a,c,d   Farzin, Mahtab ^a,d   Clarkson, Adele ^a,d   Sioson, Loretta ^a,d   Watson, Nicole ^a   Chua, Terence C ^d,f   Sztynda, Tamara ^b   Samra, Jaswinder S ^c,d,e   Gill, Anthony J ^a,c,d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ROYAL NORTH SHORE HOSPITAL   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f MACQUARIE UNIVERSITY HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BAP1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN THIOLESTERASE;

ADENOCARCINOMA; ADULT; AGED; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, PANCREATIC DUCTAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE;

EID: 85006702209     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0150338     Document Type: Article

References (44)

1. Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford) [Internet]. 2008 Feb 11; 10(2):77–82. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2504381/
2. Hidalgo M. Pancreatic CancerMedical Progress: N Engl J Med [Internet]. Boston: Massachusetts Medical Society; 2010 Apr 29; 362(17):1605–17. Available from: http://ezproxy.lib.uts.edu.au/login?url=http://search.proquest.com/docview/220112506?accountid=17095
3. Reid MD, Saka B, Balci S, Goldblum AS, Adsay NV. Molecular Genetics of Pancreatic Neoplasms and Their Morphologic Correlates: An Update on Recent Advances and Potential Diagnostic Applications. Am J Clin Pathol [Internet]. 2014 Feb 1; 141(2):168–80. Available from: http://ajcp.ascpjournals.org/content/141/2/168.abstract
4. Biankin A V, Waddell N, Kassahn KS, Gingras M-C, Muthuswamy LB, Johns AL, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature [Internet]. Nature Publishing Group; 2012 Nov 15; 491(7424):399–405. Available from: doi: 10.1038/nature11547
5. Giovinazzo F, Turri G, Zanini S, Butturini G, Scarpa A, Bassi C. Clinical implications of biological markers in Pancreatic Ductal Adenocarcinoma. Surg Oncol [Internet]. 2012 Dec [cited 2015 Feb 12]; 21 (4):171–82. Available from: http://www.sciencedirect.com/science/article/pii/S0960740412000576
6. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin [Internet]. 2015 Jan 1; 65 (1):5–29. Available from: doi: 10.3322/caac.21254
7. Frampton AE, Gall TMH, Krell J, Ahmad R, Jiao LR. Is there a “margin” for error in pancreatic cancer surgery? Futur Oncol [Internet]. London: Future Medicine Ltd; 2013 Jan; 9(1):31–4. Available from: http://ezproxy.lib.uts.edu.au/login?url=http://search.proquest.com/docview/1240926268?accountid= 17095
8. Battaglia A. The importance of multidisciplinary approach in early detection of BAP1 tumor predisposition syndrome: Clinical management and risk assessment. Clin Med Insights Oncol. 2014; 8(1):37–47.
9. Murali R, Wiesner T, Scolyer RA. Tumours associated with BAP1 mutations. Pathology [Internet]. 2013; 45(February):116–26. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23277170
10. Wiesner T, Obenauf A, Murali R, Fried I, Griewank K, Ulz P, et al. Abstract LB-125: Germline mutations in BAP1 predispose to melanocytic nevi and melanoma. Cancer Res. 2011; 43(10):1018–21.
11. Wiesner T, Murali R, Fried I, Cerroni L, Kutzner H, Bastian BC. Abstract 3671: A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression. Cancer Res. 2012; 36(6):818–30.
12. Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011; 43(10):1022–5. doi: 10.1038/ng.912 PMID: 21874000
13. Yoshikawa Y, Sato A, Tsujimura T, Emi M, Morinaga T, Fukuoka K, et al. Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma. Cancer Sci. 2012; 103(1):868–74.
14. Popova T, Hebert L, Jacquemin V, Gad S, Caux-Moncoutier V, Dubois-D’Enghien C, et al. Germline BAP1 mutations predispose to renal cell carcinomas. Am J Hum Genet. 2013; 92(1):974–80.
15. Abdel-Rahman MH, Pilarski R, Cebulla CM, Massengill JB, Christopher BN, Boru G, et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet [Internet]. 2011 Dec 1; 48(12):856–9. Available from: http://jmg.bmj.com/content/48/12/856.abstract
16. Carbone M, Yang H, Pass HI, Krausz T, Testa JR, Gaudino G. BAP1 and cancer. Nat Rev Cancer [Internet]. 2013; 13(3):153–9. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3792854&tool=pmcentrez&rendertype=abstract
17. Porpodis K, Zarogoulidis P, Boutsikou E, Papaioannou A, Machairiotis N, Tsakiridis K, et al. Malignant pleural mesothelioma: Current and future perspectives. J Thorac Dis. 2013; 5(17):397–406.
18. Arzt L, Quehenberger F, Halbwedl I, Mairinger T, Popper HH. BAP1 protein is a progression factor in malignant pleural mesothelioma. Pathol Oncol Res. 2014; 20(1):145–51. doi: 10.1007/s12253-013-9677-2 PMID: 23963927
19. Rusch A, Ziltener G, Nackaerts K, Weder W, Stahel RA, Felley-Bosco E. Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases. Lung Cancer [Internet]. 2015 Jan [cited 2015 Mar 7]; 87(1):77–9. Available from: http://www.sciencedirect.com/science/article/pii/S0169500214004516
20. Ho TH, Kapur P, Joseph RW, Serie DJ, Eckel-Passow JE, Parasramka M, et al. Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma. Urol Oncol [Internet]. 2015 Jan [cited 2015 Mar 7]; 33(1):23.e9–14. Available from: http://www.sciencedirect.com/science/article/pii/S1078143914003573
21. Piris A, Mihm MC, Hoang MP. BAP1 and BRAFV600E expression in benign and malignant melanocytic proliferations. Hum Pathol [Internet]. 2015 Feb [cited 2015 Jan 20]; 46(2):239–45. Available from: http://www.sciencedirect.com/science/article/pii/S0046817714004420
22. Chan-On W, Nairismägi M-L, Ong CK, Lim WK, Dima S, Pairojkul C, et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet [Internet]. 1] Laboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, Singapore. [2] Division of Cancer and Stem Cell Biology, Duke-National University of Singapore Graduate Medical School, Singapore. [3] Liver Fluke and Chola: Nature Pub. Co.; 2013 Dec; 45 (12):1474–8. Available from: http://search.ebscohost.com/login.aspx?direct=true&db=mnh&AN=24185513&site=ehost-live
23. Jiao Y, Pawlik TM, Anders R A, Selaru FM, Streppel MM, Lucas DJ, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet [Internet]. Nature Publishing Group; 2013; 45(12):1470–3. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4013720&tool=pmcentrez&rendertype=abstract
24. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM. Ann Surg Oncol [Internet]. 2010 Jun; 17(6):1471–4. Available from: http://www.springerlink.com/index/10.1245/s10434-010-0985-4
25. Shah AA, Bourne TD, Murali R. BAP1 protein loss by immunohistochemistry. Pathology [Internet]. 2013 Dec; 45(7):651–6. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=01268031-201312000-00004
26. Koopmans AE, Verdijk RM, Brouwer RWW, van den Bosch TPP, van den Berg MMP, Vaarwater J, et al. Clinical significance of immunohistochemistry for detection of BAP1 mutations in uveal melanoma. Mod Pathol [Internet]. 2014 Oct; 27(10):1321–30. Available from: http://www.nature.com/ doifinder/10.1038/modpathol.2014.43
27. de la Fouchardière A, Cabaret O, Savin L, Combemale P, Schvartz H. Germline BAP1 mutations predispose also to multiple basal cell carcinomas. Clin Genet. 2014; 1(15):1–5.
28. Farzin M, Toon CW, Clarkson A, Sioson L, Watson N, Andrici J, et al. Loss of expression of BAP1 predicts longer survival in mesothelioma. Pathology [Internet]. 2015 May; 47(4):302–7. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=01268031-900000000-99515
29. Haugk B. Pancreatic intraepithelial neoplasia–can we detect early pancreatic cancer? Histopathology [Internet]. Blackwell Publishing Ltd; 2010 Oct 1; 57(4):503–14. Available from: doi: 10.1111/j.1365-2559.2010.03610.x
30. Chang DK, Grimmond SM, Biankin A V. Pancreatic cancer genomics. Curr Opin Genet Dev [Internet]. 2014 Mar [cited 2015 Aug 31]; 24:74–81. Available from: http://www.sciencedirect.com/science/article/pii/S0959437X13001809
31. Waddell N, Pajic M, Patch A-M, Chang DK, Kassahn KS, Bailey P, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature [Internet]. Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.; 2015 Feb 26; 518(7540):495–501. Available from: doi: 10.1038/nature14169
32. Graham JS, Jamieson NB, Rulach R, Grimmond SM, Chang DK, Biankin A V. Pancreatic cancer genomics: where can the science take us? Clin Genet [Internet]. Blackwell Publishing Ltd; 2015 Sep 1; 88 (3):213–9. Available from: doi: 10.1111/cge.12536
33. Gonzalez-Perez A, Jene-Sanz A, Lopez-Bigas N. The mutational landscape of chromatin regulatory factors across 4,623 tumor samples. Genome Biol [Internet]. BioMed Central; 2013 Sep 24; 14(9): r106–r106. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4054018/
34. Andrici J, Goeppert B, Sioson L, Clarkson A, Tayao M, Watson N, et al. Loss of expression of BAP1 expression occurs frequently in intrahepatic cholangiocarcinoma. Manuscr Publ. 2015;
35. Putra J, de Abreu FB, Peterson JD, Pipas JM, Mody K, Amos CI, et al. Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencing. Exp Mol Pathol [Internet]. 2015 Jul 17 [cited 2015 Aug 31]; 99(2):240–4. Available from: http://www.sciencedirect.com/science/article/pii/S0014480015001537
36. Cardinale V, Semeraro R, Torrice A, Gatto M, Napoli C, Bragazzi MC, et al. Intra-hepatic and extrahepatic cholangiocarcinoma: New insight into epidemiology and risk factors. World J Gastrointest Oncol [Internet]. Baishideng Publishing Group Co., Limited; 2010 Nov 15; 2(11):407–16. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3000454/
37. Andrici J, Sheen A, Sioson L, Wardell K, Clarkson A, Watson N, et al. Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology. Mod Pathol [Internet]. United States & Canadian Academy of Pathology; 2015 Oct; 28(10):1360–8. Available from: doi: 10.1038/modpathol.2015.87
38. Andrici J, Jung J, Sheen A, D’Urso L, Sioson L, Pickett J, et al. Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma. Hum Pathol [Internet]. Elsevier; 2016 Mar 1; 51:9–15. Available from: doi: 10.1016/j.humpath.2015.12.012
39. Singhi AD, Krasinskas AM, Choudry HA, Bartlett DL, Pingpank JF, Zeh HJ, et al. The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma. Mod Pathol [Internet]. 2016 Jan 23; 29(1):14–24. Available from: http://www.nature.com/doifinder/10.1038/modpathol.2015. 121
40. Hwang HC, Sheffield BS, Rodriguez S, Thompson K, Tse CH, Gown AM, et al. Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens. Am J Surg Pathol [Internet]. 2016; 40(1). Available from: http://journals.lww.com/ajsp/Fulltext/2016/01000/Utility_of_BAP1_Immunohistochemistry_and_p16.15.aspx
41. McGregor SM, Dunning R, Hyjek E, Vigneswaran W, Husain AN, Krausz T. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma. Hum Pathol [Internet]. Elsevier; 2016 Mar 1; 46(11):1670–8. Available from: doi: 10.1016/j.humpath.2015. 06.024
42. Joseph RW, Kapur P, Serie DJ, Parasramka M, Ho TH, Cheville JC, et al. Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression. J Urol [Internet]. Elsevier; 2016 Mar 1; 195 (1):180–7. Available from: doi: 10.1016/j.juro.2015.07.113
43. Cigognetti M, Lonardi S, Fisogni S, Balzarini P, Pellegrini V, Tironi A, et al. BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations. Mod Pathol [Internet]. United States & Canadian Academy of Pathology; 2015 Aug; 28 (8):1043–57. Available from: doi: 10.1038/modpathol.2015.65
44. Mochel MC, Piris A, Nose V, Hoang MP. Loss of BAP1 Expression in Basal Cell Carcinomas in Patients With Germline BAP1 Mutations. Am J Clin Pathol [Internet]. 2015 Jun 1; 143(6):901–4. Available from: http://ajcp.oxfordjournals.org/content/143/6/901.abstract